Certolizumab pegol

Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Brand: Cimzia ®
NICE TA: 415
Indication: Rheumatoid arthritis, 2nd line after the failure of a TNF inhibitor (NICE TA415) and (LMMG RA Biologic Pathway)
Disease category: Musculoskeletal system
Commissioning responsibility: CCG
PbR excluded: Yes

Background

Treatment to be continued with the most cost effective, clinically appropriate drug (taking into account administration costs, required dose and product price per dose). This may need to be varied in individual cases due to differences in the mode of administration and treatment schedules.

Recommendation

LMMG recommendation: Red
Click here to find the definitions for the colour classifications

Reason for decision: Specialist medicine

Supporting documents:

NICE TA415 - Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor

Rheumatoid Arthritis High Cost Drugs Pathway (Version 2.1) (158.2 KiB)

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG	NHS Blackpool CCG	NHS Chorley and South Ribble CCG and NHS Greater Preston CCG	NHS Fylde and Wyre CCG	NHS Morecambe Bay CCG	NHS West Lancashire CCG
Red	Red	Red	Red	Red	Red

Medicines